Transmitted drug resistance and transmission clusters among HIV-1 treatment-naïve patients in Guangdong, China: a cross-sectional study
Tóm tắt
Transmitted drug resistance (TDR) that affects the effectiveness of the first-line antiretroviral therapy (ART) regimen is becoming prevalent worldwide. However, its prevalence and transmission among HIV-1 treatment-naïve patients in Guangdong, China are rarely reported. We aimed to comprehensively analyze the prevalence of TDR and the transmission clusters of HIV-1 infected persons before ART in Guangdong. The HIV-1 treatment-naïve patients were recruited between January 2018 and December 2018. The HIV-1 pol region was amplified by reverse transcriptional PCR and sequenced by sanger sequencing. Genotypes, surveillance drug resistance mutations (SDRMs) and TDR were analyzed. Genetic transmission clusters among patients were identified by pairwise Tamura-Nei 93 genetic distance, with a threshold of 0.015. A total of 2368 (97.17%) HIV-1 pol sequences were successfully amplified and sequenced from the enrolled 2437 patients. CRF07_BC (35.90%, 850/2368), CRF01_AE (35.56%, 842/2368) and CRF55_01B (10.30%, 244/2368) were the main HIV-1 genotypes circulating in Guangdong. Twenty-one SDRMs were identified among fifty-two drug-resistant sequences. The overall prevalence of TDR was 2.20% (52/2368). Among the 2368 patients who underwent sequencing, 8 (0.34%) had TDR to protease inhibitors (PIs), 22 (0.93%) to nucleoside reverse transcriptase inhibitors (NRTIs), and 23 (0.97%) to non-nucleoside reverse transcriptase inhibitors (NNRTIs). Two (0.08%) sequences showed dual-class resistance to both NRTIs and NNRTIs, and no sequences showed triple-class resistance. A total of 1066 (45.02%) sequences were segregated into 194 clusters, ranging from 2 to 414 sequences. In total, 15 (28.85%) of patients with TDR were included in 9 clusters; one cluster contained two TDR sequences with the K103N mutation was observed. There is high HIV-1 genetic heterogeneity among patients in Guangdong. Although the overall prevalence of TDR is low, it is still necessary to remain vigilant regarding some important SDRMs.
Tài liệu tham khảo
http://cdcp.gd.gov.cn/newsdt_list/content/post_2723203.html
Eisinger RW, Dieffenbach CW, Fauci AS. HIV viral load and transmissibility of HIV infection. Undetectable equals untransmittable. JAMA. 2019;321(5):451–2. https://doi.org/10.1001/jama.2018.21167.
Lessells RJ, Mutevedzi PC, Iwuji CC, et al. Reduction in early mortality on antiretroviral therapy for adults in rural South Africa since change in CD4+ cell count eligibility criteria. J Acquir Immune Defic Syndr. 2014;65(1):e17-24. https://doi.org/10.1097/QAI.0b013e31829ceb14.
Hingankar NK, Thorat SR, Deshpande A, et al. Initial virologic response and HIV drug resistance among HIV-infected individuals initiating first-line antiretroviral therapy at 2 clinics in Chennai and Mumbai, India. Clin Infect Dis. 2012;54(Suppl 4):S348–54. https://doi.org/10.1093/cid/cis005.
Rossouw TM, Nieuwoudt M, Manasa J, et al. HIV drug resistance levels in adults failing frst-line antiretroviral therapy in an urban and a rural setting in South Africa. HIV Med. 2017;18(2):104–14. https://doi.org/10.1111/hiv.12400.
Rhee SY, Kassaye SG, Barrow G, et al. HIV-1 transmitted drug resistance surveillanceshifting trends in study design and prevalence estimates. J Int AIDS Soc. 2020;23(9): e25611. https://doi.org/10.1002/jia2.25611.
Rudometova NB, Shcherbakova NS, Shcherbakov DN, et al. Genetic diversity and drug resistance mutations in reverse transcriptase and protease genes of HIV-1 isolates from Southwestern Siberia. AIDS Res Hum Retroviruses. 2021. https://doi.org/10.1089/AID.2020.0225.
Kantzanou M, Karalexi MA, Papachristou H, et al. Transmitted drug resistance among HIV-1 drug-naïve patients in Greece. Int J Infect Dis. 2021;105:42–8. https://doi.org/10.1016/j.ijid.2021.02.043.
Richardson D, Fitzpatrick C, Parkes L, et al. HIV-1 transmitted drug resistance in Brighton, UK, from 2014 to 2020. Int J STD AIDS. 2021;32(2):199–201. https://doi.org/10.1177/0956462420953043.
Pingarilho M, Pimentel V, Diogo I, et al. Increasing prevalence of HIV-1 transmitted drug resistance in Portugal. Implications for first line treatment recommendations. Viruses. 2020;12(11):1238. https://doi.org/10.3390/v12111238.
Zhao S, Feng Y, Hu J, et al. Prevalence of transmitted HIV drug resistance in antiretroviral treatment naïve newly diagnosed individuals in China. Sci Rep. 2018;8(1):12273. https://doi.org/10.1038/s41598-018-29202-2.
Ye J, Hao M, Xing H, et al. Characterization of subtypes and transmitted drug resistance strains of HIV among Beijing residents between 2001–2016. PLoS ONE. 2020;15(3): e0230779. https://doi.org/10.1371/journal.pone.0230779.
Pang X, Tang K, He Q, et al. HIV drug resistance and HIV transmission risk factors among newly diagnosed individuals in Southwest China. BMC Infect Dis. 2021;21(1):160. https://doi.org/10.1186/s12879-021-05854-w.
Xu Y, Peng X, Peng X, et al. Characterization of HIV-1 subtypes and transmitted drug resistance among treatment-naive HIV-infected individuals in Zhejiang, China, 2014–2017. Arch Virol. 2018;163(8):2233–7. https://doi.org/10.1007/s00705-018-3839-1.
Zheng MN, Ning TL, Zhou N, et al. Transmitted drug resistance among HIV infected men who have sex with men in Tianjin, 2014–2017. Zhonghua Liu Xing Bing Xue Za Zhi. 2018;39(5):619–24. https://doi.org/10.3760/cma.j.issn.0254-6450.2018.05.015.
Gazzard BG, Anderson J, Babiker A, et al. BHIVA Treatment Guidelines Writing Group. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008;9(8):563–608. https://doi.org/10.1111/j.1468-1293.2008.00636.x.
Hicks CB. Guideline watch. Antiretroviral drug resistance testing–updated guidelines from the IAS-USA. AIDS Clin Care. 2008;20(8):64.
Struck D, Lawyer G, Ternes AM, et al. COMETadaptive context-based modeling for ultrafast HIV-1 subtype identification. Nucleic Acids Res. 2014;42(18): e144. https://doi.org/10.1093/nar/gku739.
Pineda-Peña AC, Faria NR, Imbrechts S, et al. Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposesperformance evaluation of the new REGA version 3 and seven other tools. Infect Genet Evol. 2013;19:337–48. https://doi.org/10.1016/j.meegid.2013.04.032.
Struck D, Lawyer G, Ternes AM, et al. COMET adaptive context-based modeling for ultrafast HIV-1 subtype identification. Nucleic Acids Res. 2014;42(18): e144. https://doi.org/10.1093/nar/gku739.
Pineda-Peña AC, Faria NR, Imbrechts S, et al. Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes performance evaluation of the new REGA version 3 and seven other tools. Infect Genet Evol. 2013;19:337–48. https://doi.org/10.1016/j.meegid.2013.04.032.
Guindon S, Dufayard JF, Lefort V, et al. New algorithms and methods to estimate maximum-likelihood phylogenies assessing the performance of PhyML 3.0. Syst Biol. 2010;59(3):307–21. https://doi.org/10.1093/sysbio/syq010.
Anisimova M, Gascuel O. Approximate likelihood-ratio test for branches. A fast, accurate, and powerful alternative. Syst Biol. 2006;55(4):539–52. https://doi.org/10.1080/10635150600755453.
Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42(11):1608–18. https://doi.org/10.1086/503914.
Wertheim JO, Kosakovsky Pond SL, Forgione LA, et al. Social and genetic networks of HIV-1 transmission in New York City. PLoS Pathog. 2017;13(1): e1006000. https://doi.org/10.1371/journal.ppat.1006000.
Hassan AS, Pybus OG, Sanders EJ, et al. Defining HIV-1 transmission clusters based on sequence data. AIDS. 2017;31(9):1211–22. https://doi.org/10.1097/QAD.0000000000001470.
Wertheim JO, Kosakovsky Pond SL, et al. Social and genetic networks of HIV-1 transmission in New York City. PLoS Pathog. 2017;13(1): e1006000. https://doi.org/10.1371/journal.ppat.1006000.
Oster AM, Wertheim JO, Hernandez AL, et al. Using molecular HIV surveillance data to understand transmission between subpopulations in the United States. J Acquir Immune Defic Syndr. 2015;70(4):444–51. https://doi.org/10.1097/QAI.0000000000000809.
Whiteside YO, Song R, Wertheim JO, et al. Molecular analysis allows inference into HIV transmission among young men who have sex with men in the United States. AIDS. 2015;29(18):2517–22. https://doi.org/10.1097/QAD.0000000000000852.
Lin M, Lin P, Li H, et al. Epidemiological study on HIV/AIDS in Guangdong province. J Clin AIDS/STD Prev Cont. 2001;7(1):11–3.
He X, Xing H, Ruan Y, et al. A comprehensive mapping of HIV-1 genotypes in various risk groups and regions across China based on a nationwide molecular epidemiologic survey. PLoS ONE. 2012;7(10): e47289. https://doi.org/10.1371/journal.pone.0047289.
Zhou PP, Yu G, Kuang YQ, et al. Rapid and complicated HIV genotype expansion among high-risk groups in Guangdong Province, China. BMC Infect Dis. 2019;19(1):185. https://doi.org/10.1186/s12879-019-3788-7.
Zhang Z, Dai L, Jiang Y, et al. Transmission network characteristics based on env and gag sequences from MSM during acute HIV-1 infection in Beijing, China. Arch Virol. 2017;162(11):3329–38. https://doi.org/10.1007/s00705-017-3485-z.
Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance 2009 update. PLoS ONE. 2009;4(3): e4724. https://doi.org/10.1371/journal.pone.0004724.
Sallam M, Şahin GÖ, Indriðason H, et al. Decreasing prevalence of transmitted drug resistance among ART-naive HIV-1-infected patients in Iceland, 1996–2012. Infect Ecol Epidemiol. 2017;7(1):1328964. https://doi.org/10.1080/20008686.2017.1328964.
Kleyn TJ, Liedtke MD, Harrison DL, et al. Incidence of transmitted antiretroviral drug resistance in treatment-naive HIV-1-infected persons in a large South Central United States clinic. Ann Pharmacother. 2014;48(4):470–5. https://doi.org/10.1177/1060028013519246.
Cai XL, Lan Y, Li JB, et al. Analysis on drug resistance in HIV/AIDS patients with HAART through different infection routes in Guangdong. Chin J AIDS/STD. 2015;21(05):369–72.